Suppr超能文献

局部区域复发食管癌患者再次放疗的生存获益:倾向评分匹配分析。

Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis.

机构信息

Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, 350014, China.

Department of Radiation Oncology, Xiamen Humanity Hospital, Xiamen, China.

出版信息

Radiat Oncol. 2018 Sep 10;13(1):171. doi: 10.1186/s13014-018-1122-y.

Abstract

BACKGROUND

To investigate the treatment failure pattern and factors influencing locoregional recurrence of esophageal squamous cell carcinoma (ESCC) and examine patient survival with re-irradiation (re-RT) after primary radiotherapy.

METHODS

We retrospectively analyzed 87 ESCC patients treated initially with radiotherapy. Failure patterns were classified into regional lymph node recurrence only (LN) and primary failure with/without regional lymph node recurrence (PF). Patients received either re-RT or other treatments (non-re-RT group). Baseline covariates were balanced by a propensity score model. Overall survival (OS) and toxicities were assessed as outcomes.

RESULTS

The median follow-up time was 87 months. Thirty-nine patients received re-RT. Failure pattern and re-RT were independent prognostic factors for OS (P = 0.040 and 0.015) by Cox multivariate analysis. Re-RT with concomitant chemotherapy showed no survival benefit over re-RT alone (P = 0.70). No differences in characteristics were found between the groups by Chi-square tests after propensity score matching. The Cox model showed that failure pattern and re-RT were prognostic factors with hazard ratios (HR) of 0.319 (P = 0.025) and 0.375 (P = 0.002), respectively, in the matched cohort. Significant differences in OS were observed according to failure pattern (P = 0.004) and re-RT (P < 0.001). In the re-RT and non-re-RT groups, 9.09% and 3.03% of patients experienced tracheoesophageal fistulas, and 15.15% and 3.03% of patients developed pericardial/pleural effusion, respectively (P > 0.05). The incidence of radiation pneumonitis was higher in the re-RT group (24.24% vs. 6.06%, P = 0.039), but no cases of pneumonia-related death occurred.

CONCLUSIONS

Re-RT improved long-term survival in patients with locoregional recurrent ESCC. Despite a high incidence of radiation pneumonitis, toxicities were tolerable.

摘要

背景

本研究旨在探讨食管鳞癌(ESCC)放疗后局部区域复发的治疗失败模式和影响因素,并评估再放疗(re-RT)对初治放疗后局部区域复发患者的生存影响。

方法

我们回顾性分析了 87 例初治接受放疗的 ESCC 患者。失败模式分为单纯区域淋巴结复发(LN)和原发灶失败伴/不伴区域淋巴结复发(PF)。患者接受 re-RT 或其他治疗(非 re-RT 组)。通过倾向评分模型平衡基线协变量。以总生存(OS)和毒性为结局。

结果

中位随访时间为 87 个月。39 例患者接受 re-RT。多因素 Cox 分析显示,失败模式和 re-RT 是 OS 的独立预后因素(P=0.040 和 0.015)。同期放化疗联合 re-RT 并未改善 re-RT 患者的生存(P=0.70)。倾向性评分匹配后,两组间的特征比较无统计学差异。Cox 模型显示,在匹配队列中,失败模式和 re-RT 是预后因素,其风险比(HR)分别为 0.319(P=0.025)和 0.375(P=0.002)。根据失败模式(P=0.004)和 re-RT(P<0.001),患者的 OS 存在显著差异。在 re-RT 和非 re-RT 组中,分别有 9.09%和 3.03%的患者发生气管食管瘘,15.15%和 3.03%的患者发生心包/胸腔积液(P>0.05)。re-RT 组放射性肺炎的发生率较高(24.24% vs. 6.06%,P=0.039),但无肺炎相关死亡病例。

结论

re-RT 可改善局部区域复发 ESCC 患者的长期生存。尽管放射性肺炎的发生率较高,但毒性可耐受。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9511/6131819/42b2fa25fb10/13014_2018_1122_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验